GRI
GRI Bio, Inc.Company Information
- Company Name
- GRI Bio, Inc.
- CIK
- CIK0001824293
- Category
- <br>Emerging growth company
- Ticker: Exchange
- GRI: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- GRI
SEC filing data through
Insider Sentiment
- Last purchase
- 2021-06-04
- Last sale
- —
- Shares purchased (TTM)
- 9,308
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 64,826
- Shares outstanding
- 1,804,951
- Ownership
- 3.59%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- 72.46%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 11 | 11 | 8 | 4 | 5 | 3 | 5 | 5 | 6 | 4 | 2 | 3 | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | ||||||
| Assets Current | 11 | 11 | 9 | 5 | 6 | 4 | 6 | 5 | 7 | 4 | 3 | 4 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 11 | 11 | 9 | 5 | 6 | 4 | 6 | 5 | 7 | 5 | 3 | 4 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 0 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Accrued Liabilities Current | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Warrants And Rights Outstanding | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Notes Payable Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Liabilities Current | 1 | 1 | 3 | 3 | 2 | 3 | 2 | 2 | 2 | 2 | 3 | 2 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 1 | 1 | 3 | 3 | 2 | 3 | 2 | 2 | 2 | 2 | 3 | 2 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 66 | 64 | 58 | 51 | 49 | 44 | 44 | 41 | 40 | 36 | 32 | 32 | ||||||
| Retained Earnings Accumulated Deficit | -55 | -54 | -52 | -49 | -46 | -43 | -40 | -38 | -36 | -33 | -32 | -30 | ||||||
| Stockholders Equity | 10 | 11 | 6 | 2 | 3 | 1 | 4 | 4 | 5 | 3 | 0 | 2 | ||||||
| Liabilities And Stockholders Equity | 11 | 11 | 9 | 5 | 6 | 4 | 6 | 5 | 7 | 5 | 3 | 4 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | ||||||
| Common Stock Shares Issued | 2 | 2 | 0 | 3 | 2 | 1 | 0 | 5 | 1 | 3 | 3 | 3 | ||||||
| Shares Outstanding | 2 | 2 | 0 | 3 | 2 | 1 | 0 | 5 | 1 | 3 | 3 | 3 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialGRI Bio, Inc. (GRI) — SEC Financial Statements & Analysis
GRI Bio, Inc. (GRI) is a pharmaceutical preparations company, incorporated in DE. GRI Bio, Inc. trades on Nasdaq as: GRI. GRI Bio, Inc. (GRI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, GRI Bio, Inc. carries a market cap of $3.19M, a P/E ratio of -0.33x, a P/B ratio of 0.31x, an enterprise value of $-7.75M, and an EV/EBITDA multiple of 0.80x. On profitability, it posts a Return on Equity (ROE) of -142.01% and a Return on Assets (ROA) of -113.27%. Per share, it reports EPS of $-5.35, diluted EPS of $-5.35, free cash flow per share of $-5.77, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -18.96% year-over-year and EPS growth of -96.46% year-over-year. On the balance sheet, it maintains a current ratio of 10.30x, a quick ratio of 9.95x, working capital of $10.23M, a debt-to-equity ratio of 0.11x, a debt ratio of 0.1, an interest coverage ratio of -460.95x, free cash flow of $-10.41M (TTM), and net debt of $-10.95M. Figures sourced from SEC EDGAR.
- Market Cap
- $3.19M
- P/E TTM
- -0.33x
- EPS TTM
- $-5.35
- P/B TTM
- 0.31x
- ROE TTM
- -142.01%
- ROA TTM
- -113.27%
- Debt To Equity
- 0.11x
- Free Cash Flow TTM
- $-10.41M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is GRI Bio, Inc. in?
GRI Bio, Inc. (GRI) operates in the Pharmaceutical Preparations industry.
What exchange does GRI trade on?
GRI Bio, Inc. (GRI) trades on the Nasdaq.
Where is GRI Bio, Inc. incorporated?
GRI Bio, Inc. is incorporated in DE.
When was GRI Bio, Inc. (GRI)'s most recent SEC filing?
GRI Bio, Inc. (GRI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is GRI's market cap?
GRI Bio, Inc. (GRI) has a market capitalization of $3.19M as of 2026-06-30.
What is GRI's EPS (earnings per share)?
GRI Bio, Inc. (GRI)'s trailing twelve month EPS is $-5.35 as of 2026-06-30.
What is GRI's ROE (return on equity)?
GRI Bio, Inc. (GRI)'s trailing twelve month Return on Equity (ROE) is -142.01% as of 2026-06-30.
What is GRI's ROA (return on assets)?
GRI Bio, Inc. (GRI)'s trailing twelve month Return on Assets (ROA) is -113.27% as of 2026-06-30.
What is GRI's EV/EBITDA?
GRI Bio, Inc. (GRI)'s trailing twelve month EV/EBITDA is 0.80x as of 2026-06-30.